These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 19996412)
1. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Pennell DJ; Porter JB; Cappellini MD; El-Beshlawy A; Chan LL; Aydinok Y; Elalfy MS; Sutcharitchan P; Li CK; Ibrahim H; Viprakasit V; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A Blood; 2010 Mar; 115(12):2364-71. PubMed ID: 19996412 [TBL] [Abstract][Full Text] [Related]
2. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Pennell DJ; Porter JB; Piga A; Lai Y; El-Beshlawy A; Belhoul KM; Elalfy M; Yesilipek A; Kilinç Y; Lawniczek T; Habr D; Weisskopf M; Zhang Y; Aydinok Y; Blood; 2014 Mar; 123(10):1447-54. PubMed ID: 24385534 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Merchant R; Ahmed J; Krishnan P; Jankharia B Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861 [TBL] [Abstract][Full Text] [Related]
4. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497 [TBL] [Abstract][Full Text] [Related]
5. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major. Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199 [TBL] [Abstract][Full Text] [Related]
6. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A Haematologica; 2012 Jun; 97(6):842-8. PubMed ID: 22271905 [TBL] [Abstract][Full Text] [Related]
7. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Aydinok Y; Kattamis A; Cappellini MD; El-Beshlawy A; Origa R; Elalfy M; Kilinç Y; Perrotta S; Karakas Z; Viprakasit V; Habr D; Constantinovici N; Shen J; Porter JB; Blood; 2015 Jun; 125(25):3868-77. PubMed ID: 25934475 [TBL] [Abstract][Full Text] [Related]
8. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Wood JC; Kang BP; Thompson A; Giardina P; Harmatz P; Glynos T; Paley C; Coates TD Blood; 2010 Jul; 116(4):537-43. PubMed ID: 20421452 [TBL] [Abstract][Full Text] [Related]
9. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. Ruffo GB; Borsellino Z; Cuccia L; Marocco MR; Gagliardotto F; Tarantino R Clin Drug Investig; 2010; 30(4):267-73. PubMed ID: 20225910 [TBL] [Abstract][Full Text] [Related]
10. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y; Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran. Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712 [TBL] [Abstract][Full Text] [Related]
13. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Pathare A; Taher A; Daar S Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501 [TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Gomber S; Jain P; Sharma S; Narang M Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681 [TBL] [Abstract][Full Text] [Related]
15. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies. Fragomeno C; Roccabruna E; D'Ascola DG Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572 [TBL] [Abstract][Full Text] [Related]
17. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508 [TBL] [Abstract][Full Text] [Related]
19. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A; Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979 [TBL] [Abstract][Full Text] [Related]
20. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan. Chang HH; Lu MY; Peng SS; Yang YL; Lin DT; Jou ST; Lin KH Ann Hematol; 2015 Dec; 94(12):1945-52. PubMed ID: 26404899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]